Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.

Van Dam PS, Smid HE, de Vries WR, Niesink M, Bolscher E, Waasdorp EJ, Dieguez C, Casanueva FF, Koppeschaar HP

The Journal of clinical endocrinology and metabolism1 Dec 2000Cited by 17 (Europe PMC)

PMID11134132DOI10.1210/jcem.85.12.7087PepBankPUB-11134132

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialActivity measurement
In healthy elderly men, the GH response to GHRP‑2 alone was 4.8 times higher than to GHRH alone.
In plain wordsIn healthy elderly men, GHRP‑2 released 4.8 times more growth hormone than GHRH did.
Peptide
GHRP-2
Outcome
IncreaseGH AUC after GHRP-2 compared with GHRH
Study
n = 9
Comparator
GHRH alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
GH AUC
1834 microg/L.60 min
GHRP-2 alone
GH AUC
382 microg/L.60 min
GHRH alone
Source sentences
Summary
The area under the curve (AUC) of the GH response after GHRP-2 alone was 4.8 times higher compared with GHRH alone (1834 +/- 255 vs. 382 +/- 78 microg/L.60 min, P: < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated GH releasing capacity in nine healthy elderly men after administration of GH-releasing peptide 2 (GHRP-2), with or without pretreatment with the antilipolytic drug acipimox, and compared the GHRP-2-induced GH release with the response to GHRH.
Report a problemFND-1113413201
02HumanRandomized controlled trialMechanism
In healthy elderly men, GHRP‑2 administration was followed by a significant early rise in plasma FFAs by 60%.
In plain wordsIn healthy elderly men, GHRP‑2 was followed by an early rise in blood fatty acids.
Peptide
GHRP-2
Outcome
IncreaseEarly rise in plasma FFAs after GHRP-2
Study
n = 9
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Plasma FFA rise
60%
after GHRP-2
Source sentences
Summary
Interestingly, GHRP-2 administration was followed by a significant early rise in plasma FFAs by 60% (P = 0.01), indicating an acute lipolytic effect.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated GH releasing capacity in nine healthy elderly men after administration of GH-releasing peptide 2 (GHRP-2), with or without pretreatment with the antilipolytic drug acipimox, and compared the GHRP-2-induced GH release with the response to GHRH.
Report a problemFND-1113413205

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

03HumanNot a test of GHRP-2 aloneRandomized controlled trialActivity measurement
In healthy elderly men, acipimox pretreatment increased the GH AUC after GHRP‑2 to 2956 microg/L.60 min.
In plain wordsIn healthy elderly men, the fat-lowering drug acipimox raised the growth hormone response to GHRP‑2.
Peptide
GHRP-2
Outcome
IncreaseGH AUC after acipimox plus GHRP-2
Study
n = 9
Comparator
GHRP-2 alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
2956 microg/L.60 min
acipimox then GHRP-2
Source sentences
Summary
Acipimox, which reduced FFAs from 607 micromol/L to 180 micromol/L, increased the GH AUC to 1087 after GHRH and to 2956 microg/L.60 min after GHRP-2 (P: < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated GH releasing capacity in nine healthy elderly men after administration of GH-releasing peptide 2 (GHRP-2), with or without pretreatment with the antilipolytic drug acipimox, and compared the GHRP-2-induced GH release with the response to GHRH.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1113413202
04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy elderly men, the GH AUC after acipimox plus GHRP‑2 correlated positively with the AUC after GHRP‑2 alone (r = 0.93).
In plain wordsIn healthy elderly men, men who responded more to GHRP‑2 alone also responded more after acipimox.
Peptide
GHRP-2
Outcome
Not applicableCorrelation of GH AUC after acipimox/GHRP-2 with GHRP-2 alone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The AUC after acipimox/GHRP-2 were positively correlated with the AUC after GHRP-2 alone (r = 0.93, P: < 0.01); this was also observed between acipimox/GHRH and GHRH alone (r = 0.73, P: = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated GH releasing capacity in nine healthy elderly men after administration of GH-releasing peptide 2 (GHRP-2), with or without pretreatment with the antilipolytic drug acipimox, and compared the GHRP-2-induced GH release with the response to GHRH.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1113413203
05HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy elderly men, basal FFAs correlated negatively with the GH AUC after GHRP‑2 (r = 0.48, P = 0.04).
In plain wordsIn healthy elderly men, higher blood fat levels were linked to a smaller growth hormone response to GHRP‑2.
Peptide
GHRP-2
Outcome
DecreaseCorrelation of basal FFAs with GH AUC after GHRP-2
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Significant negative correlations were observed between basal FFAs and AUC after GHRH or GHRP-2 after combining the data with and without acipimox (r = 0.58, P: = 0.01 and r = 0.48, P: = 0.04, respectively), and between basal FFAs and GH at t = 0 (r = -0.44, P: = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated GH releasing capacity in nine healthy elderly men after administration of GH-releasing peptide 2 (GHRP-2), with or without pretreatment with the antilipolytic drug acipimox, and compared the GHRP-2-induced GH release with the response to GHRH.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1113413204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.